<DOC>
	<DOC>NCT00491127</DOC>
	<brief_summary>The purpose of this study it to evaluate efficacy of gemcitabine with cisplatin and dexamethasone in patients with aggressive non-Hodgkin's lymphoma who have previously progressed on first line of chemotherapy with anthracyclines.</brief_summary>
	<brief_title>Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>The patients must have a histological diagnosis of aggressive nonHodgkinâ€™s lymphoma including the following subcategories of the WHO classification: Diffuse large Bcell lymphoma and its variants (immunoblastic, Burkittlike, sclerosis of mediastinum, large Bcell MALT, rich in Tcells and anaplastic Bcell lymphoma) Peripheral Tcell lymphoma Anaplastic lymphoma of large Tcells /null cells Patients are eligible if they have documented evidence of progression after prior firstline chemotherapy containing anthracyclines associated or not with Rituximab. Patients with refractory disease to first line of treatment are also eligible. ECOG PS (performance status) less than or equal to 2 Presence of bidimensionally measurable disease in accordance with WHO criteria. Involvement of the CNS. Any medical condition which contraindicates the degree of hydration required for the safe use of cisplatin. Intermediate degree lymphoma derived from the malignant transformation of a previous lowgrade lymphoma. Active infection (in the opinion of the investigator).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>